Oncotarget

Research Papers:

Deletion of 18q is a strong and independent prognostic feature in prostate cancer

Martina Kluth, Maximilian Graunke, Christina Möller-Koop, Claudia Hube-Magg, Sarah Minner, Uwe Michl, Markus Graefen, Hartwig Huland, Raisa Pompe, Frank Jacobsen, Andrea Hinsch, Corinna Wittmer, Patrick Lebok, Stefan Steurer, Franziska Büscheck, Till Clauditz, Waldemar Wilczak, Guido Sauter, Thorsten Schlomm and Ronald Simon _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:86339-86349. https://doi.org/10.18632/oncotarget.13404

Metrics: PDF 1306 views  |   HTML 2369 views  |   ?  


Abstract

Martina Kluth1,*, Maximilian Graunke1,*, Christina Möller-Koop1, Claudia Hube-Magg1, Sarah Minner1, Uwe Michl2, Markus Graefen2, Hartwig Huland2, Raisa Pompe2, Frank Jacobsen1, Andrea Hinsch1, Corinna Wittmer1, Patrick Lebok1, Stefan Steurer1, Franziska Büscheck1, Till Clauditz1, Waldemar Wilczak1, Guido Sauter1, Thorsten Schlomm2,3, Ronald Simon1

1Institute of Pathology, Prostate Cancer Center at University Medical Center Hamburg-Eppendorf, Germany

2Martini-Clinic, Prostate Cancer Center at University Medical Center Hamburg-Eppendorf, Germany

3Department of Urology, Section for prostate cancer research, University Medical Center Hamburg-Eppendorf, Germany

*These authors contributed equally to this work

Correspondence to:

Ronald Simon, email: [email protected]

Keywords: 18q deletion, prostate cancer, prognosis, tissue microarray

Received: September 27, 2016     Accepted: November 02, 2016     Published: November 16, 2016

ABSTRACT

Deletion of 18q recurrently occurs in prostate cancer. To evaluate its clinical relevance, dual labeling fluorescence in-situ hybridization (FISH) using probes for 18q21 and centromere 18 was performed on a prostate cancer tissue microarray (TMA). An 18q deletion was found in 517 of 6,881 successfully analyzed cancers (7.5%). 18q deletion was linked to unfavorable tumor phenotype. An 18q deletion was seen in 6.4% of 4,360 pT2, 8.0% of 1,559 pT3a and 11.8% of 930 pT3b-pT4 cancers (P < 0.0001). Deletions of 18q were detected in 6.9% of 1,636 Gleason ≤ 3 + 3, 6.8% of 3,804 Gleason 3 + 4, 10.1% of 1,058 Gleason 4+3, and 9.9% of 344 Gleason ≥ 4 + 4 tumors (P = 0.0013). Deletions of 18q were slightly more frequent in ERG-fusion negative (8.2%) than in ERG-fusion positive cancers (6.4%, P = 0.0063). 18q deletions were also linked to biochemical recurrence (BCR, P < 0.0001). This was independent from established pre- and postoperative prognostic factors (P ≤ 0.0004). In summary, the results of our study identify 18q deletion as an independent prognostic parameter in prostate cancer. As it is easy to measure, 18q deletion may be a suitable component for multiparametric molecular prostate cancer prognosis tests.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13404